Gil T - Search Results

1

Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.

Maiter D, Bex M, Vroonen L, T'Sjoen G, Gil T, Banh C, Chadarevian R. Maiter D, et al. Among authors: gil t, t sjoen g. Ann Endocrinol (Paris). 2016 Oct;77(5):578-585. doi: 10.1016/j.ando.2016.02.005. Epub 2016 Apr 7. Ann Endocrinol (Paris). 2016. PMID: 27063476

2

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. Schöffski P, et al. Among authors: gil t. BJU Int. 2011 Sep;108(5):679-86. doi: 10.1111/j.1464-410X.2010.09947.x. Epub 2010 Dec 13. BJU Int. 2011. PMID: 21156020 Clinical Trial.

3

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. Schöffski P, et al. Among authors: gil t. Eur J Cancer. 2013 Oct;49(15):3219-28. doi: 10.1016/j.ejca.2013.06.010. Epub 2013 Jul 5. Eur J Cancer. 2013. PMID: 23835252 Clinical Trial.

4

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Bolla M, et al. Among authors: gil t. N Engl J Med. 1997 Jul 31;337(5):295-300. doi: 10.1056/NEJM199707313370502. N Engl J Med. 1997. PMID: 9233866 Free article. Clinical Trial.

5

Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.

Prenen H, Dumez H, Stefan C, Hoeben A, Wouters C, Van Lierde MA, Sciot R, van Oosterom AT, Peeters M, Polus M, Duck L, Gil T, Schöffski P. Prenen H, et al. Among authors: gil t. Acta Gastroenterol Belg. 2006 Oct-Dec;69(4):367-71. Acta Gastroenterol Belg. 2006. PMID: 17343077 Clinical Trial.

6

Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.

Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D'Hondt V. Rosa DD, et al. Among authors: gil t. Arch Gynecol Obstet. 2008 Nov;278(5):457-62. doi: 10.1007/s00404-008-0592-9. Epub 2008 Feb 14. Arch Gynecol Obstet. 2008. PMID: 18273626 Clinical Trial.

7

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.

Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J. Awada A, et al. Among authors: gil t. Br J Cancer. 2008 May 6;98(9):1500-7. doi: 10.1038/sj.bjc.6604347. Epub 2008 Apr 29. Br J Cancer. 2008. PMID: 18454159 Free PMC article. Clinical Trial.

8

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G. Schöffski P, et al. Among authors: gil t. Eur J Cancer. 2012 Jan;48(2):179-86. doi: 10.1016/j.ejca.2011.11.001. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119200 Clinical Trial.

9

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T. Awada A, et al. Among authors: gil t. Eur J Cancer. 2012 Mar;48(4):465-74. doi: 10.1016/j.ejca.2011.12.026. Epub 2012 Jan 27. Eur J Cancer. 2012. PMID: 22285181 Clinical Trial.

10

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, D'Hondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A. de Azambuja E, et al. Among authors: gil t. Ann Oncol. 2013 Dec;24(12):2985-9. doi: 10.1093/annonc/mdt359. Epub 2013 Sep 7. Ann Oncol. 2013. PMID: 24013582 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters